What Is the SmartPill and Why Was It Discontinued?

The SmartPill was an ingestible wireless capsule that measured pH, pressure, and temperature as it traveled through the entire digestive tract, giving doctors a detailed picture of how quickly food moved through the stomach, small intestine, and colon in a single, non-invasive test. It was cleared by the FDA in 2006 and used clinically for over a decade before its manufacturer, Medtronic, quietly phased it out of production. The discontinuation left a genuine gap in gastroenterology, because no other single test could profile motility across all three gut regions at once, and the clinical community is still working to fill it.

What the SmartPill Actually Did

The SmartPill was about the size of a large vitamin capsule. A patient swallowed it after eating a standardized meal, and as the capsule moved through the gut, it continuously transmitted data to a small receiver worn on the body. Three sensors did the work. A pH sensor tracked acidity changes, which is how the device knew when it left the stomach (a sharp rise in pH signals entry into the small intestine) and when it entered the colon (a drop in pH marks the ileocecal junction). A pressure sensor recorded the strength and pattern of gut contractions along the way. A temperature sensor added another data point. After the capsule passed naturally, typically within one to five days, a clinician downloaded the recorded data and analyzed it using proprietary software.

The practical upshot was that one swallowed capsule could produce transit times for the stomach, small bowel, and colon, plus a whole-gut transit time. This was a big deal because the existing tests for motility each covered only one region. Gastric emptying scintigraphy, the gold standard for gastroparesis, tells you about the stomach but nothing about the colon. Radiopaque marker studies assess colonic transit but ignore the upper gut. The SmartPill did both and everything in between.

How It Compared to Established Tests

The clinical case for the SmartPill rested on validation studies that pitted it against the older, established methods. For gastric emptying, the key comparison was with scintigraphy, a nuclear medicine test where you eat a radiolabeled meal and get scanned at intervals. In one study, the time the capsule spent in the stomach correlated strongly with how much of the radiolabeled meal was still in the stomach at two hours, with a correlation coefficient of 0.95.¹ A separate study using simultaneous SmartPill and scintigraphy testing found moderate but meaningful correlations between the capsule’s gastric residence time and scintigraphic measures of solid-phase emptying.²

For colonic transit, the comparator was radiopaque markers, small plastic rings you swallow that show up on X-rays taken days later. A multicenter study of patients with chronic constipation found roughly 87% overall agreement between the SmartPill and radiopaque markers for distinguishing slow from normal colonic transit.³ Another study reported a diagnostic accuracy of 0.73 for the SmartPill in predicting constipation from colonic transit time, with specificity reaching 0.95, numbers that were comparable to the radiopaque marker method.⁴

These numbers were good enough to earn the SmartPill clinical credibility, but they were not perfect. The correlations with scintigraphy for gastric emptying were strongest in the first couple of hours and less tight at four hours. There is also an inherent apples-to-oranges element in these comparisons: scintigraphy tracks how a digestible meal leaves the stomach, while the SmartPill itself is a non-digestible object. The capsule empties from the stomach by a different mechanism than food does, swept out by the powerful “housekeeper” contractions that clean the stomach between meals. That mismatch means the SmartPill’s gastric transit time and a scintigraphic half-emptying time are related but not identical measures.

The Unique Selling Point That Nothing Else Offered

Where the SmartPill truly stood apart was in its ability to profile motility across the entire gut in one go. A review of its clinical use highlighted that patients who came in with symptoms suggesting a problem in one region often turned out to have abnormal transit in multiple regions.⁵ A patient referred for suspected gastroparesis might also have slow colonic transit, and vice versa. No combination of scintigraphy plus radiopaque markers could catch both in a single test without multiple visits, radiation exposure from the scintigraphy, and days of waiting for the marker X-rays.

Data presented by Given Imaging, the company that marketed the SmartPill before Medtronic acquired it, indicated that SmartPill results changed diagnosis frequently and led to medication changes for most patients who had abnormal results. Even when the test came back normal, it altered clinical management in over half of those cases, often by steering doctors away from unnecessary further testing or empiric treatments.⁶

Safety and Side Effects

The SmartPill had a reassuring safety record. The main risk with any ingestible capsule device is retention, meaning the capsule gets stuck somewhere in the gut instead of passing naturally. For the SmartPill used in motility assessment, the retention rate was about 0.3%, which is substantially lower than the retention rates reported for video capsule endoscopy, where the figure ranges from roughly 2% to over 8% depending on the patient population.⁷ The difference makes sense: capsule endoscopy is often used in patients with Crohn’s disease or other conditions that cause narrowing in the bowel, while the SmartPill was typically used in patients with functional motility complaints and structurally normal guts.

Swallowing difficulty was reported at a rate of about 0.6% in post-marketing data, which again compares favorably to capsule endoscopy’s rate of about 1.5%.⁷ The capsule was contraindicated in patients with known strictures, severe dysphagia, or implanted medical devices that could interact with it. For the vast majority of patients who met the eligibility criteria, though, it was a straightforward and well-tolerated procedure.

Use in Children and Adolescents

One area where the SmartPill showed particular promise was pediatric motility testing. The alternatives are harder to justify in kids: scintigraphy involves radiation, antroduodenal manometry requires placing a nasal tube into the small intestine under sedation, and neither is pleasant for a child. A study of pediatric patients with suspected gastroparesis and dysmotility found that the SmartPill had 100% sensitivity for detecting gastroparesis compared with a two-hour scintigraphic study, and it picked up motor abnormalities in more patients than antroduodenal manometry did.⁸ The capsule was well tolerated in all patients, with no side effects.

A smaller study in adolescents echoed those findings. Nine patients with functional gastrointestinal symptoms completed the test without complications, and the results led to therapy changes in patients where delayed gastric emptying or colonic transit was identified. In two cases, the SmartPill findings directly guided the addition of prokinetic medication, which improved or resolved symptoms.⁹ For a population where non-invasive testing is especially valued, losing the SmartPill was a real setback. A systematic review of gastroparesis testing in pediatrics noted that while alternative tests like breath tests exist, they suffer from a lack of standardization, and gastric emptying scintigraphy remains the default largely because nothing else has achieved the same level of validation.¹⁰

Why Medtronic Stopped Making It

The SmartPill’s journey through corporate ownership tells much of the story. It was originally developed by SmartPill Corporation, a small medical device company. Given Imaging, best known for its PillCam video capsule, acquired the SmartPill product line. Then in 2014, Medtronic acquired Given Imaging as part of a broader deal to build out its gastrointestinal business. Medtronic is a massive company with a portfolio spanning cardiac devices, surgical robotics, and diabetes management. Within that portfolio, a niche motility capsule with a small addressable market apparently did not justify the ongoing investment in manufacturing, regulatory maintenance, and technical support.

No dramatic safety recall or regulatory action drove the discontinuation. The SmartPill was not pulled from the market because it failed; it was quietly phased out, reportedly because the commercial return did not meet the threshold a company of Medtronic’s size requires. This is a common fate for orphaned medical devices: a product that works well for a relatively small patient population gets acquired by a larger company and then deprioritized when it does not contribute meaningfully to the bottom line. Recent clinical literature now routinely refers to the SmartPill as a “discontinued reference standard” when comparing newer technologies against it.¹¹

For gastroenterologists who relied on the SmartPill, the frustration is real. The device had a solid evidence base, a favorable safety profile, and a unique clinical niche. Its discontinuation was a business decision, not a scientific one.

What Doctors Fell Back On

With the SmartPill gone, clinicians reverted to the older, region-specific tests. For gastric emptying, that means scintigraphy, which involves eating a radiolabeled egg sandwich (or similar standardized meal) and sitting through imaging at one, two, three, and four hours. It remains the gold standard, but it requires a nuclear medicine facility, exposes the patient to a small amount of radiation, and tells you nothing about what happens downstream of the stomach.

For colonic transit, the fallback is the radiopaque marker study. You swallow a capsule containing 24 small plastic rings, then get an abdominal X-ray five days later. The number of retained markers indicates whether transit is slow. It is cheap and widely available, but it comes with a limitation worth knowing about: a study of chronic constipation patients found that the number of retained markers correlated poorly with how bad patients actually felt. Symptom severity and quality of life showed almost no relationship to the marker count.¹² That disconnect suggests the test captures one dimension of colonic function but misses others that matter to patients.

Neither of these tests gives you the whole-gut profile that was the SmartPill’s signature capability. If a doctor wants to know about both the stomach and the colon, the patient now has to undergo two separate tests on separate days, each with its own preparation and limitations.

Emerging Capsule Technologies Trying to Fill the Gap

Several groups have been developing next-generation ingestible capsules designed to step into the void the SmartPill left. The most advanced is the Atmo Capsule, a gas-sensing device that measures hydrogen, carbon dioxide, and oxygen concentrations as it transits the gut. Those gas profiles serve as landmarks for identifying gut regions, similar to how the SmartPill used pH changes. In a multicenter study of over 200 participants, gastric emptying and colonic transit times measured by the Atmo Capsule correlated strongly with simultaneous SmartPill measurements, with agreement reaching 84% for identifying delayed transit in both the stomach and the colon.¹¹ A separate analysis of the Atmo Capsule in patients with confirmed motility disorders reported sensitivity of 0.83 and specificity of 0.96 for detecting delayed gastric emptying, and sensitivity of 0.79 and specificity of 0.84 for delayed colonic transit.¹³

These are encouraging numbers, though not yet the near-perfect agreement you would want before declaring a full replacement. The Atmo Capsule’s sensitivity for delayed gastric emptying, at 68% in the larger trial, suggests it misses about a third of cases that the SmartPill would have caught. The colonic transit numbers are more robust. Development is ongoing, and the device is not yet widely available for clinical use.

Another approach under investigation is the 3D-Transit system, which uses electromagnetic tracking to follow a capsule’s real-time position inside the abdomen. A pilot study combined the 3D-Transit capsule with a wireless motility capsule into a single unit, allowing simultaneous tracking of spatial position and intraluminal pressure and pH. The combined device was well tolerated and produced detailed contraction pattern data throughout the gut.¹⁴ This is early-stage work, but it hints at a future where capsule-based motility testing could offer even richer information than the SmartPill did.

Why Whole-Gut Motility Testing Still Matters

Gastroparesis and chronic constipation are common conditions, but they are also often parts of a broader motility problem. A patient with diabetes-related gastroparesis may also have slow colonic transit. A patient with idiopathic constipation may have unrecognized delayed gastric emptying contributing to nausea and early fullness. Without a whole-gut test, these overlapping problems go undetected, and treatment addresses only part of the picture.

The SmartPill’s pressure data also had value beyond transit timing. Contraction patterns throughout the gut gave additional clues about whether the muscular wall of the intestine was functioning properly or whether the nerves coordinating motility were impaired. That granularity was lost along with the device itself.

For now, the clinical community is in an awkward in-between period. The SmartPill set a standard for comprehensive, non-invasive motility assessment, but the market forces that govern medical device availability do not always align with clinical need. The next-generation capsules show promise, but none has yet achieved the regulatory clearance, widespread availability, and body of validation data that the SmartPill accumulated over its years in use. Gastroenterologists who remember what the SmartPill could do are watching these developments closely, hoping that the gap in their diagnostic toolkit will not last much longer.